NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

A型血友病 - 流行病學預測:2030年

Hemophilia A - Epidemiology - 2030

出版商 DelveInsight Business Research LLP 商品編碼 923586
出版日期 按訂單生產 內容資訊 英文 120 Pages
商品交期: 10個工作天內
價格
A型血友病 - 流行病學預測:2030年 Hemophilia A - Epidemiology - 2030
出版日期: 按訂單生產內容資訊: 英文 120 Pages
簡介

主要7個國家 (美國、德國、西班牙、義大利、法國、英國、日本)的A型血友病的總患者數在2017年達到42,458人,診斷、治療的總患者數是38,212人。

本報告提供全球A型血友病治療藥市場相關調查分析,疾病的背景,流行病學,主要7個國家的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 摘要整理

第3章 A型血友病:疾病的背景和概要

  • 簡介
    • A型血友病的症狀
    • A型血友病的遺傳模式
    • A型血友病的分子病理
    • A型血友病的病理生理學
    • A型血友病的危險因素
  • A型血友病的診斷
    • 診斷的確立
    • 分子遺傳學的檢驗
    • 篩檢檢驗
    • 凝血因子檢驗
    • 抑制劑實驗

第4章 流行病學和患者族群

  • 流行病學的主要調查結果
  • 前提條件與根據:主要7個國家
  • 流行病學方案:主要7個國家

第5章 美國的流行病學

  • 確診的整體盛行率
  • 重病度固有的盛行率
  • 抑制劑有沒有/的盛行率

第6章 EU5個國家的各國流行病學

  • 德國的流行病學
  • 法國的流行病學
  • 義大利的流行病學
  • 西班牙的流行病學
  • 英國的流行病學

第7章 日本的流行病學

  • 確診的整體盛行率
  • 重病度固有的盛行率
  • 抑制劑有沒有/的盛行率

第8章 附錄

第9章 DelveInsight的功能

第10章 免責事項

第11章 關於DelveInsight

目錄
Product Code: DIEI0617

DelveInsight's Hemophilia A- Epidemiology-2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Hemophilia A - Disease Understanding and Treatment Algorithm

Hemophilia A is an X chromosome-linked genetic disorder caused by the mutations in the genes for factor VIII (FVIII). This clotting factor is a part of the intrinsic pathway of blood coagulation. Without enough factor VIII, the blood cannot clot properly to control bleeding. It is mainly a defect in the gene on chromosome X, females have two copies of the X chromosome. So, if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII. On the other hand, males have only one X chromosome; if the factor VIII gene is missing on the male X chromosome, he will have hemophilia A that is why the most people with Hemophilia A are male.

The symptoms of Hemophilia A can vary greatly from one person to another, it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.

Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.

The treatment of Hemophilia A is mainly focused on the prophylaxis as there is no cure for hemophilia A. Treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder. Replacement of this protein may be obtained through recombinant factor VIII, which is artificially created in a lab. Several recombinant forms of factor VII are also approved for the treatment of hemophilia A. In some cases, subjects with hemophilia A may develop 'inhibitors' against the replacement factor VIII. Inhibitors are antibodies, which are specialized proteins created by the body's immune system to combat foreign or invading substances such as toxins or bacteria. The immune system may recognize replacement factor VIII as 'foreign' and create these antibodies (inhibitors), which target and destroy the replacement factor. For inhibitors treatment is mainly dependent on bypassing agents and immne tolerance therapy (ITI).

Hemophilia A-Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors] scenario of Hemophilia A in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

DelveInsight's analysts have assessed that the total prevalent population of Hemophilia A in the 7MM was 42,458 in 2017. In addition to this, it was accessed that the total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.

DelveInsight's estimate suggests that the United States witnessed the highest number of cases with Hemophilia A, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 14,200 cases in 2017. Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy. On the other hand, the Spain had the lowest prevalent population of Hemophilia A in 2017. Furthermore, Japan had 5,297 prevalent cases for Hemophilia A in 2017.

It was also observed that Severe Hemophilia A cases are more prominent in comparison to Mild and Moderate. In the United States, observed number of mild cases were 3,195, i.e., 25% of the diagnosed and Treated Hemophilia A patient pool in 2017. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool. Among the Hemophilia A patients, i.e., with or without/Non-Inhibitors, the latter one accounts for a higher number of Hemophilia A cases.

Report Scope

  • The report covers a detailed overview of Hemophilia A explaining its causes, symptoms, classification, and pathophysiology.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors.

Hemophilia A Report Key Strengths

  • 11-Year Forecast
  • 7MM Coverage
  • Total Prevalence of Hemophilia A
  • Diagnosed and Treated Prevalent Population of Hemophilia A
  • Severity-Specific Prevalence of Hemophilia A
  • Prevalence of Hemophilia A with Inhibitors and without Inhibitors

Hemophilia A Report Assessment

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary

3. Hemophilia A: Disease Background and Overview

  • 3.1. Introduction
    • 3.1.1. Sign and Symptoms of Hemophilia A
    • 3.1.2. Inheritance Pattern of Hemophilia A
    • 3.1.3. Molecular Pathogenesis of Hemophilia A
    • 3.1.4. Pathophysiology of Hemophilia A
    • 3.1.5. Risk Factors of Hemophilia A
  • 3.2. Diagnosis of Hemophilia A
    • 3.2.1. Establishing the Diagnosis
    • 3.2.2. Molecular Genetic Testing
    • 3.2.3. Screening Tests
    • 3.2.4. Clotting Factor Tests
    • 3.2.5. Inhibitor Testing

4. Epidemiology and Patient Population

  • 4.1. Epidemiology Key Findings
  • 4.2. Assumptions and Rationale: 7MM
  • 4.3. Epidemiology Scenario: 7MM
    • 4.3.1. Total Diagnosed Prevalence of Hemophilia A in the 7MM
    • 4.3.2. Severity- Specific Prevalence of Hemophilia A in the 7MM
    • 4.3.3. Prevalence of Hemophilia A with or without Inhibitors the 7MM

5. United States Epidemiology

  • 5.1. Total Diagnosed Prevalence of Hemophilia A in the United States
  • 5.2. Severity- Specific Prevalence of Hemophilia A in the United States
  • 5.3. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States

6. EU-5 Country-wise Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Total Diagnosed Prevalence of Hemophilia A in Germany
    • 6.1.2. Severity- Specific Prevalence of Hemophilia A in Germany
    • 6.1.3. Prevalence of Hemophilia A with or without Inhibitors in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Total Diagnosed Prevalence of Hemophilia A in France
    • 6.2.2. Severity- Specific Prevalence of Hemophilia A in France
    • 6.2.3. Prevalence of Hemophilia A with or without Inhibitors in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Total Diagnosed Prevalence of Hemophilia A and B in Italy
    • 6.3.2. Severity-Specific Prevalence of Hemophilia A in Italy
    • 6.3.3. Prevalence of Hemophilia A with or without Inhibitors in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Total Diagnosed Prevalence of Hemophilia A in Spain
    • 6.4.2. Severity- Specific Prevalence of Hemophilia A in Spain
    • 6.4.3. Prevalence of Hemophilia A with Inhibitors or Without-Inhibitors in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Total Diagnosed Prevalence of Hemophilia A in the United Kingdom
    • 6.5.2. Severity- Specific Prevalence of Hemophilia A in the United Kingdom
    • 6.5.3. Prevalence of Hemophilia A with Inhibitors or Non-Inhibitors in the United Kingdom

7. Japan Epidemiology

  • 7.1. Total Diagnosed Prevalence of Hemophilia A in Japan
  • 7.2. Severity- Specific Prevalence of Hemophilia A in Japan
  • 7.3. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1 Summary of Hemophilia A Epidemiology (2017-2030)
  • Table 2 Summary of sources explored for the epidemiology of Hemophilia A
  • Table 3 Total Diagnosed Prevalence of HemophiliaA in the 7MM (2017-2030)
  • Table 4 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017-2030)
  • Table 5 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017-2030)
  • Table 6 Total Diagnosed Prevalence of Hemophilia A in the United States (2017-2030)
  • Table 7 Severity- Specific Prevalence of Hemophilia A in the US (2017-2030)
  • Table 8 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States (2017-2030)
  • Table 9 Total Diagnosed Prevalence of Hemophilia A in Germany (2017-2030)
  • Table 10 Severity- Specific Prevalence of Hemophilia A in Germany (2017-2030)
  • Table 11 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017-2030)
  • Table 12 Total Diagnosed Prevalence of Hemophilia A in France (2017-2030)
  • Table 13 Severity- Specific Prevalence of Hemophilia A in France (2017-2030)
  • Table 14 Prevalence of Hemophilia A with or Non-Inhibitors in France (2017-2030)
  • Table 15 Total Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Table 16 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Table 17 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017-2030)
  • Table 18 Total Diagnosed Prevalence of Hemophilia A in the Spain (2017-2030)
  • Table 19 Severity-Specific Prevalence of Hemophilia A in Spain (2017-2030)
  • Table 20 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017-2030)
  • Table 21 Total Diagnosed Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Table 22 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Table 23 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017-2030)
  • Table 24 Total Diagnosed Prevalence of Hemophilia A in Japan (2017-2030)
  • Table 25 Severity- Specific Prevalence of Hemophilia A in Japan (2017-2030)
  • Table 26 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017-2030)

List of Figures

  • Figure 1 Coagulation Cascade and the Effects of Recombinant Activated Factor Vll (rFVlla)
  • Figure 2 Inheritance Pattern of Hemophilia A
  • Figure 3 Established and Proposed Risk Factors for Inhibitor Development
  • Figure 4 Screening Tests for Hemophilia A
  • Figure 5 Total Diagnosed Prevalence of HemophiliaA in the 7MM (2017-2030)
  • Figure 6 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017-2030)
  • Figure 7 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017-2030)
  • Figure 8 Total Diagnosed Prevalence of Hemophilia A in the United States (2017-2030)
  • Figure 9 Severity- Specific Prevalence of Hemophilia A in the US (2017-2030)
  • Figure 10 Prevalence of Hemophilia A with Inhibitors & Without Inhibitors in the United States (2017-2030)
  • Figure 11 Total Diagnosed Prevalence of Hemophilia A in Germany (2017-2030)
  • Figure 12 Severity- Specific Prevalence of Hemophilia A in Germany (2017-2030)
  • Figure 13 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017-2030)
  • Figure 14 Total Diagnosed Prevalence of Hemophilia A in France (2017-2030)
  • Figure 15 Severity- Specific Prevalence of Hemophilia A in France (2017-2030)
  • Figure 16 Prevalence of Hemophilia A with or Non-Inhibitors in France (2017-2030)
  • Figure 17 Total Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Figure 18 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Figure 19 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017-2030)
  • Figure 20 Total Diagnosed Prevalence of Hemophilia A in the Spain (2017-2030)
  • Figure 21 Severity-Specific Prevalence of Hemophilia A in Spain (2017-2030)
  • Figure 22 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017-2030)
  • Figure 23 Total Diagnosed Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Figure 24 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Figure 25 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017-2030)
  • Figure 26 Total Diagnosed Prevalence of Hemophilia A in Japan (2017-2030)
  • Figure 27 Severity- Specific Prevalence of Hemophilia A in Japan (2017-2030)
  • Figure 28 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017-2030)